In December 2017, the US Food and Drug Administration (FDA) provided approval for voretigene neparvovec-rzyl (LuxturnaTM), a gene therapy developed explicitly for the treatment of vision loss and Leber congenital amaurosis 2 (LCA2), a congenital retinal degenerative disorder. Here, RPE65 is linked to Leber congenital amaurosis.